drugset
drugset / Trial / NCT00852670

ACT-128800 in Psoriasis

NCT00852670 ↗

Phase 2 Completed 66 enrolled Actelion
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will assess the efficacy, safety, and tolerability of ACT-128800 in subjects with moderate to severe plaque psoriasis.

Timeline

Start
2008-10
Primary completion
2009-07
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Ponesimod Small molecule — Oral

Indications

psoriasis